Abstract 937P
Background
Pain, fatigue and depression are commonly seen in cancer survivors and may co-occur. The extent of these symptoms occurring, alone or together, in head and neck cancer (HNC) is unknown. Using data from the Head and Neck 5000 cohort, we (i) investigated prevalence of the pain, fatigue, depression symptom cluster and (ii) explored its association with health-related quality of life (HRQoL).
Methods
Sociodemographic and clinical data were collected from participants at cohort recruitment (pre-treatment). At 12-months post-recruitment, cancer-related pain, fatigue and HRQoL were measured using the EORTC QLQ-C30, and depression using the Hospital Anxiety & Depression Scale (HADS). Cut-offs to define presence of clinically-important symptoms were: pain ≥25, fatigue ≥39 and depression ≥8. Associations between HRQoL score (on scale 1-100; higher score=better HRQoL) and the symptom cluster (0/1/2/3 symptoms), adjusted for clinical and sociodemographic variables, were assessed using multivariate linear regression.
Results
2,207 patients were included in the analysis. 47.3% had one or more symptoms of pain, fatigue or depression at clinically important levels. 20.3% had any one symptom, 13.7% had any two symptoms and 13.4% had all three symptoms. In the multivariate analysis, number of symptoms was strongly associated with HRQoL. After adjusting for other variables, presence of any one symptom was associated with a 13.4 point decrease (95% CI -15.2 to -11.7) in HRQoL, any two symptoms with a 26.3 point decrease (95% CI -28.3 to -24.3) and all three symptoms with a 42.3 point decrease (95% CI -44.3 to -40.2) in the HRQoL.
Conclusions
There is a high prevalence of the pain, fatigue and depression cluster in HNC survivors with over one in ten experiencing all three symptoms at 12-months. They have a significant negative impact on HRQoL. More attention should be given to identifying survivors experiencing this symptom cluster. Interventions targeted at addressing the cluster symptoms may help improve HRQoL amongst HNC survivors.
Clinical trial identification
N/A
Editorial acknowledgement
Funding
National Institute for Health and Care Research (NIHR).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1025P - Fully intravenous delivery regimen of oncolytic adenovirus coding for TNFa and IL-2 (TILT-123) in patients with advanced solid cancers
Presenter: Santeri Pakola
Session: Poster session 03
1026P - Updated results from the phase I 1456-0001 study for intratumoral (IT) VSV-GP (BI 1831169) in patients with advanced solid tumors
Presenter: Stephane Champiat
Session: Poster session 03
1027P - First results for intravenous (IV) VSV-GP (BI 1831169) in patients (pts) with advanced solid tumors from the 1456-0001 study
Presenter: Marc Oliva Bernal
Session: Poster session 03
1028P - A phase I study of personalized KSX01-TCRT therapy for advanced solid tumor and its mechanisms
Presenter: Shuhang Wang
Session: Poster session 03
Resources:
Abstract
1029P - Preclinical development of TCR-modified T cell therapies against mutated KRAS
Presenter: Hugh Salter
Session: Poster session 03
1030P - Survival rates in high-risk neuroblastoma patients undergoing anti-GD2 immunotherapy: A single arm meta-analysis and systemic review
Presenter: Lorena Escalante Romero
Session: Poster session 03
1032P - Tumor-infiltrating lymphocytes with inducible membrane-tethered IL-12 cultured in optimized media exhibits superior anti-tumor activity
Presenter: Patrick Innamarato
Session: Poster session 03
1033P - Anti-tumor efficacy and safety of conditionally activated armored CAR-T cells against gastrointestinal tumors
Presenter: Zhihong Huang
Session: Poster session 03
1034P - Preclinical development of genetically modified tumor-infiltrating lymphocytes using biopsy samples from liver cancer patients
Presenter: Mingyu Liu
Session: Poster session 03
1035P - A new IL-6 inducing mechanism in cancer with new therapeutic possibilities
Presenter: Leif Håkansson
Session: Poster session 03